Clinical trials located in


Bilbao city is located in Spain. Currently, 19 clinical trials are being conducted in this city.

Bilbao, nestled in Spain’s Basque Country, is a vibrant city renowned for its transformation from an industrial heartland to a cultural hub. The iconic Guggenheim Museum, a masterpiece of contemporary architecture by Frank Gehry, symbolizes this metamorphosis. Bilbao’s Old Town (Casco Viejo) offers a contrast with its narrow streets and historic buildings. The city is also famous for its culinary scene, particularly pintxos, the local take on tapas. Bilbao’s commitment to art, design, and sustainability has made it a model for urban regeneration worldwide.

  • CT-EU-00116193

    Efficacy and safety study of rosnilimab in moderate to severe rheumatoid arthritis

    This study will evaluate the effectiveness and safety of Rosnilimab in patients with moderate to severe rheumatoid arthritis. Rosnilimab is an antibody that activates the PD-1 receptor, also known as ANB030. Patients will be randomly assigned to receive Rosnilimab or placebo.

    The main aim of the study is to assess changes in the 28-Joint Disease Activity Index based on the concentration of C-reactive protein (DAS28-CRP) after 12 weeks of treatment. DAS28-CRP is a validated tool that assesses disease activity based on the number of painful and swollen joints and the concentration of C-reactive protein in the blood. A reduction in DAS28-CRP indicates an improvement in the patient’s condition.

    This study aims to test whether Rosnilimab is effective and safe in the treatment of rheumatoid arthritis. If the results are promising, this drug could become a new treatment option for patients suffering from this disease.

  • Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    BelgiumBulgariaCzechiaFinlandFranceGermanyGreeceHungaryItalyNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    AustriaBelgiumCzechiaFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing Nipocalimab’s effect on adults with Muscle Weakness

    This study is about a new drug called nipocalimab for patients with a disease called Myasthenia Gravis (MG). MG patients feel weak in their muscles, and nipocalimab potentially could help to lessen this weakness. The drug functions by attaching itself to certain components of the blood to lessen the reaction causing muscle weakness. This large-scale study will take place in multiple hospitals and is organized in different phases including initial checks (4 weeks), treatment (24 weeks) and follow-ups (up to 2 years). It will be measured how well the treatment works through daily activity scores and strength tests.

  • Comparing the effects of Follitropin Alfa and Follitropin Delta on Ovarian Response

    This study looked at two medicines to help women get pregnant, REKOVELLE and GONAL-F, which contain Follitropin Delta and Follitropin Alfa. These drugs stimulate a woman’s body to release more eggs, which increases the chance of conception. The study will start by giving women 15 g of REKOVELLE or 225 IU. GONAL-F and see which one helps your body produce more eggs. During the procedure, various measurements will be taken, such as counting the eggs collected during the visit, examining the ovaries using ultrasound, and checking the levels of hormones in the blood. The study will also check the effectiveness of egg fertilization and their development into healthy cells called blastocysts. This data may help better understand these two treatments and their effects.

    AustriaFranceItalySpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Study of secukinumab treatment for Giant Cell Arteritis

    This study is testing a drug called Secukinumab to see if it is safe and effective in people with a disease known as giant cell arteritis (GCA). GCA affects blood vessels in the body, causing inflammation. In this study, patients will receive Secukinumab or placebo (a treatment without active medicine) along with a medicine called glucocorticoids, the dose of which will be gradually reduced. The test will test whether a 26-week treatment course is more effective than the current 52-week treatment course. The research team will monitor whether the inflammation subsides and does not return throughout the year. The team will also check how long it will take until the disease symptoms return, how many glucocorticosteroids the patient will need within a year and how his quality of life has improved.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNorwayPolandPortugalSpainSwedenUnited Kingdom
  • Testing the effectiveness and safety of ianalumab for Sjogren’s Syndrome

    This is a study called NEPTUNUS-1. In it, the researchers are testing a drug called ianalumab. It’s designed to help people who suffer from Sjogren’s syndrome, which is a condition that causes dry eyes and mouth, among other things. The main aim is to find out how this drug affects people’s symptoms. It involves two groups of people. One will receive the drug, while the other will receive a placebo (a kind of pretend medicine that doesn’t do anything). Neither the people nor the doctors will know who’s getting what until the end. This is done to make sure the results are as fair as possible. The researchers will measure how people’s symptoms change over time.

  • Study on Tolebrutinib’s ability to delay disability progression in multiple sclerosis

    This is a study that involves a specific type of multiple sclerosis (MS) called primary progressive multiple sclerosis (PPMS). In this study, a drug called SAR442168, also known as Tolebrutinib, will be tested against a placebo. The main purpose of the study is to see if this drug can slow down the progression of disability in PPMS. The researchers will also look at the drug’s effect on clinical markers, brain images (MRI), thinking abilities, physical function, and quality of life. They will also consider the safety and tolerability of this drug. How long each person will take the drug can vary, but it will be somewhere between 12 and 60 months.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Assessing long-term safety of asciminib therapy in Chronic Myelogenous Leukemia

    This trial serves as a follow-up study for individuals who participated in a previous Novartis-sponsored investigation involving the medication asciminib. The primary objective is to monitor any potential long-term side effects that may arise in individuals who have continued taking Asciminib beyond the initial study. This global study is conducted across numerous hospitals and clinics and is characterized as ‘open-label,’ signifying that participants are aware that they are receiving asciminib. During each visit, the team will assess and record whether participants continue to experience benefits from asciminib.

    AustriaBulgariaCzechiaDenmarkFranceGermanyItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Testing new plant-based energy supplement’s impact on malnutrition

    The aim of this study is to compare the effectiveness of the new plant-based liquid nutritional supplement Fortimel PlantBased in supporting weight gain in malnourished patients compared to a standard nutritional drink containing cow’s milk protein. Fortimel PlantBased was developed to meet the need for a dietary supplement that does not contain animal products, suitable for people who are malnourished due to various diseases, limit the consumption of animal products and people who cannot tolerate cow’s milk. Two groups took part in the study: one will receive Fortimel PlantBased, and the other will consume a standard cow’s milk protein drink. Participants diagnosed with malnutrition and requiring a nutritional supplement for at least 12 weeks will be monitored for weight gain and improved nutritional status. The primary goal is to evaluate the effectiveness of a plant-based dietary supplement compared to its traditional equivalent.

  • Belimumab study for systemic sclerosis-lung disease

    This study evaluates belimumab’s efficacy and safety compared to a placebo in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD). Approximately 300 participants will receive belimumab or a placebo alongside standard therapy. The main focus is on the drug’s impact on lung function, skin thickening, and symptoms affecting quality of life, like fatigue. The study aims to provide insights into better managing SSc-ILD, improving patient outcomes.

    BelgiumDenmarkFinlandFranceGermanyGreeceItalySpainUnited Kingdom
  • CT-EU-00036742

    Monitoring RSV vaccine safety in post-vaccination pregnancies

    This study tracks the safety of the RSVPreF3 vaccine in women who had it during previous pregnancies. It’s focused on women who are pregnant again after receiving the vaccine and will assess the health of both mothers and their babies. The study’s main aim is to understand any potential impacts of the vaccine on pregnancy outcomes and infant health. This research is important as it provides vital information on the safety of RSV vaccines in pregnant women, contributing to public health knowledge.

  • Asthma control study with budesonide and formoterol inhaler for adults and teens

    This is a 24-week medical study looking at the effectiveness and safety of a combined budesonide and formoterol fumarate inhaler. This inhaler is for grown-ups and teenagers who have asthma that isn’t under good management. The study wants to see if the combined inhaler works better than just using the budesonide inhaler or another available treatment. In this study, there will be three groups using different inhalers, but they won’t know which one they’re taking to ensure fairness. We measure effectiveness by seeing if their asthma symptoms get better and if they’re using less of their emergency relief inhaler. We will also be asking them questions about their quality of life with asthma.

  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

  • A study of the safety and efficacy of corvalimab compared with eculizumab in people with paroxysmal nocturnal hemoglobinuria

    This clinical study aims to evaluate the safety and efficacy of crovalimab vis-à-vis eculizumab in managing paroxysmal nocturnal hemoglobinuria (PNH), an uncommon genetic blood disorder. The study welcomes participants who’ve been receiving treatment for PNH with either eculizumab or ravulizumab for no less than three months. Also, the lactate dehydrogenase levels of the participants need to be within the threshold of twice the upper limit of normal. An agreement to fully abide by all the study visits and procedures is mandatory for interested participants. Women of childbearing potential must agree to either stay abstinent or use contraception throughout the study and for a certain period after the last dosage.

    BelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom

See more clinical trials in other cities in Spain: